Last reviewed · How we verify
Melphalan and bortezomib
Melphalan and bortezomib is a Small molecule drug developed by Dartmouth-Hitchcock Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | Melphalan and bortezomib |
|---|---|
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Neutropenia
- Thrombocytopenia
- Anaemia
- Diarrhoea
- Nausea
- Constipation
- Pyrexia
- Neuropathy peripheral
- Fatigue
- Peripheral Sensory Neuropathy
- Vomiting
- Asthenia
Key clinical trials
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (PHASE2)
- HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib (PHASE2)
- UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (PHASE3)
- Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (PHASE3)
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (PHASE3)
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (PHASE2)
- Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melphalan and bortezomib CI brief — competitive landscape report
- Melphalan and bortezomib updates RSS · CI watch RSS
- Dartmouth-Hitchcock Medical Center portfolio CI
Frequently asked questions about Melphalan and bortezomib
What is Melphalan and bortezomib?
Melphalan and bortezomib is a Small molecule drug developed by Dartmouth-Hitchcock Medical Center.
Who makes Melphalan and bortezomib?
Melphalan and bortezomib is developed by Dartmouth-Hitchcock Medical Center (see full Dartmouth-Hitchcock Medical Center pipeline at /company/dartmouth-hitchcock-medical-center).
What development phase is Melphalan and bortezomib in?
Melphalan and bortezomib is in Phase 1.
What are the side effects of Melphalan and bortezomib?
Common side effects of Melphalan and bortezomib include Neutropenia, Thrombocytopenia, Anaemia, Diarrhoea, Nausea, Constipation.